Background Prognostic factors in patients with localized primary cutaneous malignant melanoma (CMM) are well
Introduction
The incidence of cutaneous malignant melanoma (CMM) has increased rapidly in the last decades in most Western countries. 1 The 5-year relative survival is 85-90% in western Europe. 2 However, the prognosis of the patient is highly dependent on disease stage, where the relative 5-year survival of patients in stage III varies between 40% and 70% and reported as low as 10% for patients in stage IV. 3, 4 Prognostic factors for death in localized invasive CMM are well documented in various studies across the world and also in studies using data from the population-based Swedish Melanoma Register (SMR). 3, [5] [6] [7] [8] [9] A worse prognosis in patients with localized primary CMM is related to increasing age, male sex, nodular histogenetic type, increasing tumour thickness, presence of tumour ulceration and also presence of mitoses in T1 CMM. 3, [5] [6] [7] [8] [9] However, few studies have used multivariable analyses to identify prognostic risk factors for first recurrence, including locoregional and distant metastases in stages I-II CMM patients. [10] [11] [12] Most previous studies have used selected hospital-based data, but only one has used population-based data. 10 Population-based analyses would demonstrate an unbiased proportion of recurrences and the CMM-specific survival and be of importance in planning customized follow-up strategies for different groups of CMM patients. Since 1996, clinicopathological data for all primary CMMs in Sweden have been prospectively collected in the populationbased nationwide SMR covering 99% of all CMM patients in the Swedish cancer registry. 9 The County of € Osterg€ otland a region consisting of approximately 5% of the Swedish population since 1999 registered all healthcare contacts in a care data warehouse (CDW), and in addition, the Department of pathology in € Osterg€ otland provides a database with all information on metastases sent to pathology. SMR linked to these databases would therefore be a very useful source in identifying type of CMM recurrence.
The aim of this study was to identify prognostic risk factors for first recurrence in patients with localized stages I-II CMM using population-based regional data.
Materials and methods

Data collection
Using the unique 10-digit Swedish personal identity number, 13 the following population-based registers were linked; the Swedish cancer registry, SMR, the Swedish cause of death registry, care data warehouse in € Osterg€ otland (CDW) and a census registry. Data were also linked to registries from the Department of Pathology and the Department of Radiology at Link€ oping University Hospital.
Between 1999 and 2012, 1599 patients with invasive CMMs diagnosed in the County of € Osterg€ otland were identified in the Swedish cancer registry. Twenty-two patients with previous CMMs diagnosed before 1999 were excluded. Patients with a positive sentinel node biopsy (SNB) (n = 42), patients in clinical stage III (n = 26), in stage IV (n = 22) or with missing stage at diagnosis (n = 50) were also excluded from the analyses. The remaining 1437 stages I-II patients were used in further analyses with follow-up through 31 December 2012 via cause of death registry and the census registry. Patient data were then linked to the SMR to obtain the following variables: clinical stage at diagnosis according to the American Joint Commission on Cancer (AJCC-2009) classification, 3 tumour thickness, ulceration, site of the primary tumour, Clark's level of invasion, histogenetic type and result of SNB. From CDW, patients with CMM-related metastases were identified by ICD-10 codes C77.0-79.9 (secondary tumours). Information about radiotherapy and chemotherapy treatment was identified by ICD-10 codes Z510 and Z511, respectively. From the Department of Pathology, CMM metastases were identified by morphology code M87206 and site of metastases were identified by topology codes. From the Department of Radiology, data were collected in cases of difficulty to assess the information from CDW and from the Department of Pathology. Collected information was classified as follows: (i) local/satellite/ in-transit metastases, (ii) regional lymph node metastasis, (iii) distant skin, subcutaneous or nodal metastases (M1a), (iv) lung metastases (M1b) or (v) all other visceral metastases (M1c). M1a-c was classified according to the AJCC-2009 classification. 3 If a patient was registered in the Swedish cause of death registry as having died of CMM without a registered metastasis, the patient was classified as M19 (site unknown) and date of death was used as date of metastasis.
This study was approved by the Regional Ethics review board at Link€ oping University (2012/303-31).
Statistical analysis
In all analyses, age was categorized into three groups (≤54, 55-69 and ≥70 years) with similar number of patients. Tumour thickness was analysed as a categorical variable grouped as T1 (≤1.0 mm), T2 (1.01-2.0 mm), T3 (2.01-4.0 mm) and T4 (>4.0 mm).
14 In most analyses, local/satellite/in-transit metastases and regional lymph node metastasis were combined into locoregional metastases and M1a, MIb, M1c and M19 into distant metastases. Survival time was calculated from the date of diagnosis until date of the event or to the date of censoring. In the survival analyses, death from CMM was selected as the primary event. Censoring was made at the time-point of patient moved outside the County of € Osterg€ otland, death from causes other than CMM or the cut-off date 31 December 2012. Time to recurrence was calculated from the date of diagnosis until date of locoregional or distant metastasis, whichever occurred first or the date of censoring. Distant metastasis-free (distant-free) time was calculated from the date of diagnosis until date of distant metastasis or to the date of censoring.
CMM-specific survival, distant-free survival (DFS) and recurrence-free survival (RFS) were estimated using the method of Kaplan and Meier. Risk of recurrence was analysed in a Cox's proportional hazard regression presenting the independent prognostic impact for each variable and category. The prognostic impacts were expressed as hazard ratios (HRs) with 95% CIs.
In patients with localized CMM at diagnosis and later having locoregional metastasis, the increased risk for having distant metastasis was evaluated by introducing a time-dependent variable in a Cox model. Patients were regarded as stages I or II until the time-point of a locoregional metastasis and were then regarded as stage III.
Patients with missing data (n = 54) on any of the histopathological variables were excluded from the multivariable analyses. A chi-square test was used to compare distributions. Statistical significance was indicated by P-values <0.05.
Results
Of the 1437 patients diagnosed with a first primary stages I-II CMM in county of € Osterg€ otland between 1999 and 2012, 723 (50.3%) were women. Men had a median age of 64.5 years at diagnosis compared to 59 years for women. The median tumour thickness was 0.9 mm for men and 0.8 mm for women (P = 0.01). The number of patients diagnosed with primary CMMs increased during the study period, and >50% of the patients were diagnosed between 2008 and 2012 (Table 1) .
A total of 173 patients (12.0%) had a recurrence, either locoregional or distant. The risk of recurrence was significantly lower for women 8.7% than for men 15.4% (P < 0.001) ( Table 2 ; Fig. 1 ). Regional lymph node metastatic CMM (42.8%) was most common among first recurrences followed by distant metastases (37.6%) and local/satellite/in-transit metastases (19.7%). The median time after diagnosis of the primary CMM to recurrence was 1.3 years (range 0.1-10.7). Time varied significantly between type of first metastases, where time to locoregional metastases was 1.1 years (range 1.1-9.3) and time to distant metastases was 1.9 years (range 0.1-11) (P = 0.04). Time to first recurrence also varied with tumour thickness, where median time to first metastasis was 2.3 years (range 0.2-9.1) for patients with tumour thickness ≤1.0 mm and 0.8 years (range 0.1-9.3) for patients with tumours thickness >4.0 mm.
The 5-and 10-year RFS were 85.7% and 81.2%, respectively. Risk of recurrence varied significantly with age and sex. Women aged 55-69 years had the highest 5-year RFS with 95.5%. In the multivariable analysis, sex was an independent risk factor for recurrence, where women had 50% lower risk of recurrence than men (HR = 0.5, 95% CI 0.4-0.7). There was also a significant higher risk for patients ≥70 compared to patients 55-69 years (HR = 1.7, 95% CI 1.2-2.5) after adjustments for all important histopathological factors. Other significant prognostic factors for the risk of recurrence were tumour thickness, presence of ulceration, Clark's level of invasion, NM and ALM vs. SSM (Table 2) . The 5-and 10-year DFS was 88.8% and 84.5, respectively. The 5-year DFS varied with sex and age from 97.0% for women 55-69 years to 77.0% for men 70 years or older. In patients with distant metastases, M1c was the most common first site of metastases (65%). There was no significant difference in distribution of site of metastases between men and women (P = 0.84).
Ninety-nine of 127 patients with distant metastases were followed at the oncology clinic, Link€ oping University Hospital, Eighteen patients (14%) with distant metastasis were treated on clinics other than oncology and/or surgical clinics. Seventeen of these patients had no previous locoregional metastasis. The median age at distant metastasis for these patients was 85.5 years (range 66-97) representing the elderly patients in the cohort. The median time from diagnosis of the primary CMM to distant metastasis was 1.7 years (range 0.1-11) for these patients.
In patients with locoregional metastases as first recurrence (n = 108), 62 (57.4%), patients subsequently developed distant metastases with a median time of 0.7 years (range 0-5.2). Women with locoregional metastases were less likely to develop distant metastases (44.7%) than men (64.3) (P = 0.05), but there were no significant differences according to age (P = 0.61) or if the first metastasis was a regional lymph node metastasis or a local/satellite/in-transit metastasis (P = 0.06).
In a time-dependent Cox analysis, after adjusting for sex, age, period of diagnosis, site of the primary tumour, histogenetic type, tumour thickness, Clark's level of invasion and ulceration, a diagnosed locoregional metastatic disease was found to increase the risk of distant metastasis by 13 times (HR = 13.2, 95% CI 8.7-20).
The 5-and 10-year CMM-specific survival was 90.2 and 84.6, respectively. In total, 114 (7.9%) patients died due to CMM. Of these, 76 (10.6%) were men and 38 (5.3%) women. In 127 patients with distant metastases, 13 were still alive at end of follow-up. Three women and one man with primary stages I-II CMM with a registered CMM death had no previous recorded metastases. All of these four patients were 86 years or older. Excluding these four patients in an alternative multivariable Cox analysis did not affect the results.
Discussion
To our knowledge, this is one of the first population-based reports presenting prognostic factors in a multivariable setting of over 1400 patients with primary stages I-II CMMs including recurrence data. In the present study, the most important prognostic risk factor for recurrence (locoregional/distant) was increasing tumour thickness. Another important finding was that even after adjusting for age, period of diagnosis, site of primary tumour, histogenetic type, tumour thickness, Clark's level of invasion and tumour ulceration, women had an independent 50% reduced risk of recurrence compared to men. These differences confirm the results from earlier studies and might be due to behavioural factors with women being diagnosed earlier with primary CMMs. 15, 16 Biological sex differences may be of importance specifically in more advanced disease compared to the impact of early detection. 15, 17 The prognostic factors found in this study are in accordance with previous studies, [10] [11] [12] with somewhat different focus on (T-stage and SNB). Our results show similar results as another Swedish population-based study. 6 This indicates that the important prognostic factors for recurrence and CMM death coincide. The large proportion of patients (114/173) with recurrence actually died from CMM. Although the risk of recurrence was very low in patients with tumour thickness ≤1.0 mm, the total number of patients with metastases was almost as high as in patients with tumour thickness 1.01-2.0 mm. This is probably due to the fact that the proportion of patients with tumour thickness ≤1.0 has increased over time and now consists of over 50% of the CMM patients. 18 Nearly 60% of patients with locoregional metastases later developed distant metastases. Women with locoregional metastases had somewhat lower risk of later developing distant metastases than men independent of age. A previous study on patients with stage III at primary diagnosis also showed heterogenic survival outcome between men and women. 19 For patients with distant metastases, M1c (65%) was the dominating site which could be compared to AJCC data (stage IV at primary diagnosis) where the proportion of M1c was 58%. 3 In the present study, 37.6% of the patients with recurrences developed distant metastases without previous locoregional metastases indicating haematogenous metastases. 20 This result falls within the range of proportions found in previous studies (25.3-44.9)%, but varies depending on whether the study was population-based or not. 12, [20] [21] [22] [23] [24] [25] In a previously mentioned Swedish population-based study, this proportion was found to be somewhat lower (32.9%), but patients with CMM death without previous metastases were excluded, 23 but in this study included (n = 4). In our population-based study, a few patients with a registered CMM death and no previous metastases were included and also patients with metastatic disease with no recorded contact with the Department of Oncology, Link€ oping University Hospital, were included. We find this a better reflection of the clinical setting. This report indicates that identifying metastases in an early stage only through clinical examination may be difficult as a relatively high proportion of these CMM patients developed distant metastases without previous locoregional recurrences. Also, the results from this study show that it is difficult to predict distant metastases at the individual level as the first recurrence. CMM is a highly genetically heterogenic disease with a high mutational load which makes it problematic to identify patients at high risk for distant metastases by only using clinical and histopathological factors. Thus, prognostic molecular biomarkers are warranted. Considerable differences in CMM follow-up routines worldwide [26] [27] [28] [29] [30] might motivate randomized/ health economic studies comparing different follow-up systems. Moreover, during the study period, effective treatment options for metastasized CMMs were limited and also no or few clinical trials using targeted therapies or immune checkpoint blockers were performed in the south-eastern region of Sweden. The rapid development of effective novel therapies in advanced CMM has also changed the treatment landscape for patients with locoregional disease that may receive neo-/adjuvant systemic targeted or immune modulating treatment within or outside clinical trial. [31] [32] [33] A strength with the SMR register is that it has an almost complete coverage of primary CMMs and missing values for important histopathological factors are low. A great weakness is unfortunately that no recurrence data are collected in the SMR. This study has shown that recurrence data could be collected from other registries in a region in Sweden with good structured data. A previous Swedish study from the Stockholm/Gotland region studied stage-specific risk of progression/recurrence. 10 The proportion of patients with metastasis found in that study was somewhat higher compared to our findings, but the inclusion criteria differed as the study included clinical stages III-IV patients and also patients with a positive SNB. Furthermore, the methodology was a bit different; instead of using structured pathology and diagnosis data, they used text-mining algorithms in the patient records at the oncology and pathology departments. Perhaps a combination of the two methodologies could be used to create a faster and more reliable way of collecting metastases data for entire Sweden. The outcome of SNB in patients diagnosed during the early years of the study was not available because SNB was not fully implemented in the national guidelines until 2007. Patients with clinically undetectable lymph node micrometastasis were classified into stages I and II before 2007 and afterwards into stage III CMM and were therefore excluded from the present analysis. The results in this study are only valid for patients without information of SNB or patients with a negative SNB. A positive SNB significantly increases the risk of recurrence. 11 A recent large population-based study from Sweden also showed that the risk of dying from CMM was three times higher after a positive SNB compared to a negative SNB. 6 Tumour thickness was found to be the predominant risk factor for recurrence. The prognostic factors for recurrence coincided with prognostic factors for CMM death. The most common site of first recurrence in stages I-II CMM is regional lymph node (42.8%) closely followed by distant metastases (37.6%), a fact which has to be taken into consideration when choosing follow-up strategies.
